AWM
PTGX icon

Avior Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Avior Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$318 – 3364
2024
Q1 		$318 Buy
+11
New +$299 ﹤0.01% 2706

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Avior Wealth Management's PTGX Position: Q2 2024 in Review

Avior Wealth Management sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 11 shares — an estimated $318 sold.

Avior Wealth Management first reported a position in PTGX in Q1 2024 and held it in 1 quarter. The position peaked at $318 in Q1 2024. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Avior Wealth Management reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 11 Protagonist Therapeutics shares in Q2 2024, an estimated $318.
  • Avior Wealth Management first reported a position in Protagonist Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Protagonist Therapeutics position peaked at $318 in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.